In the wake of AstraZeneca’s impressive Q2 earnings, CEO Pascal Soriot emphasized the need for a more equitable distribution of global pharmaceutical research and development costs. Soriot highlighted the unsustainable burden placed on the U.S. in supporting R&D for the entire world and called for richer countries to share in these expenses.
This call for collaboration comes amidst discussions around European pharmaceutical tariffs and President Trump’s proposed drug pricing plan. Despite facing pipeline challenges in its oncology segment, particularly delays in key studies like the AVANZAR trial, AstraZeneca’s performance in Q2 exceeded expectations. The company’s robust product revenues, driven by successful oncology drugs like Enhertu, Truqap, Tagrisso, and Imfinzi, showcase its resilience and innovation in the competitive pharmaceutical landscape.
Read more from biospace.com